Patients with mCRC bearing KRAS mutations, are unlikely to benefit from the targeted therapy, showing lower response rates, decreased progression free survival (PFS), and overall survival (OS), compared with the CRC patients with wild‐type KRAS (WTKRAS).4, 5 Studies have shown that KRAS mutation status is associated with non‐responsiveness,3, 6, 7 indicating that this treatment modality is restricted to patients with WTKRAS. Here, KRAS is linked to colorectal carcinoma.